ProMIS Reports First Human PMN310 Target Engagement In Alzheimer's Disease; Stock Up

ProMIS Neurosciences reported first human evidence for its lead Alzheimer’s candidate PMN310, showing it can reduce toxic amyloid-beta oligomers in cerebrospinal fluid. The data were presented at AAIC 2026, supporting the drug’s target engagement and potential disease-modifying direction. No efficacy magnitude or trial metrics were provided in the excerpt, so near-term impact is likely limited.

Analysis

ProMIS Neurosciences reported first human evidence for its lead Alzheimer’s candidate PMN310, showing it can reduce toxic amyloid-beta oligomers in cerebrospinal fluid. The data were presented at AAIC 2026, supporting the drug’s target engagement and potential disease-modifying direction. No efficacy magnitude or trial metrics were provided in the excerpt, so near-term impact is likely limited.